Clinical Trial Update: Prevention of Vision Loss in Patients With Age-Related Macular Degeneration (AMD) by Intravitreal Injection of Bevacizumab and Ranibizumab [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial update assessing prevention of vision loss in age-related macular degeneration using intravitreal bevacizumab and ranibizumab.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Age-related Macular Degeneration

Drugs mentioned

• Avastin (bevacizumab)
• Lucentis (ranibizumab)

Snippet

Sponsor: Klinikum Bremen-Mitte, gGmbH | Conditions: Age-Related Neovascular Macular Degeneration | Phase 3 | Status: UNKNOWN